SPRB Company Profile and Key Details

Q: Who are the executives of SPRB?

Dr. Libbie Mansell M.B.A., Ph.D.Chief Regulatory & Quality OfficerDr. Ralph William Charlton III, M.D.Chief Medical OfficerMs. P. J. RamtinSenior Vice President of Bus. OperationsDr. Mojtaba Noursalehi Ph.D.Senior Vice President of BiometricsDr. Javier Szwarcberg M.D., M.P.H.Chief Executive Officer & DirectorMr. Samir M. Gharib CPA, CPA, M.B.A.Pres & Chief Financial Officer

NASDAQ : SPRB

Spruce Biosciences

$54.35

-1.39-2.49%

At Close 4:00 PM

58.74

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Spruce Biosciences, Inc. (SPRB) stock declined over -2.49%, trading at $54.35 on NASDAQ, down from the previous close of $55.74. The stock opened at $56.22, fluctuating between $53.90 and $56.74 in the recent session.

Stock Snapshot

55.74

Prev. Close

149.59M

Market Cap

53.9

Day Low

-1.37

P/E Ratio

-39.78

EPS (TTM)

-0.81

Cash Flow per Share

56.22

Open

2.75M

Number of Shares

56.74

Day High

59.2%

Free Float in %

1.86

Book Value

113.03K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2026	55.61	57.50	54.03	54.35	113.03K
Sep 09, 2026	58.52	59.01	55.70	55.74	91.86K
Sep 08, 2026	57.39	60.51	56.60	59.09	172.94K
Sep 04, 2026	57.37	58.19	56.57	57.93	103.94K
Sep 03, 2026	59.76	60.32	57.30	57.71	113.46K
Sep 02, 2026	56.52	60.13	56.52	59.67	268.13K
Sep 01, 2026	58.01	58.05	55.34	55.60	58.13K
Aug 31, 2026	60.54	60.90	57.58	58.97	44.94K
Aug 28, 2026	62.12	62.98	59.90	60.78	39.96K
Aug 27, 2026	62.00	63.56	60.55	63.30	80.3K
Aug 26, 2026	64.50	64.50	60.46	61.48	91.77K
Aug 25, 2026	58.82	64.15	58.00	63.40	147.09K
Aug 24, 2026	53.04	58.92	51.16	58.65	138.7K
Aug 21, 2026	52.48	53.00	49.03	51.58	62.29K
Aug 20, 2026	52.83	52.89	50.50	51.99	21.64K
Aug 19, 2026	54.18	54.93	52.02	52.96	88.34K
Aug 18, 2026	51.31	53.95	50.80	52.85	71.35K
Aug 17, 2026	51.57	53.60	48.92	52.92	34.8K
Aug 14, 2026	50.14	52.64	48.55	52.64	42.21K
Aug 13, 2026	47.33	51.25	47.31	49.77	50.69K

Contact Details

South San Francisco, CA 94080

United States

https://www.sprucebio.com 415 655 4168

About Company

Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.

Stock Peers

ARGX

-18.27-1.82%

argenx SE$984.04 REGN

-14.39-1.78%

Regeneron Pharmaceuticals, Inc.$793.26 MDGL

-13.54-2.48%

Madrigal Pharmaceuticals, Inc.$533.12 VRTX

-6.56-1.26%

Vertex Pharmaceuticals Incorporated$514.56 UTHR

-2.96-0.58%

United Therapeutics Corporation$503.86 KRYS

-2.54-0.73%

Krystal Biotech, Inc.$345.55 ONC

-9.2-2.62%

BeOne Medicines AG$341.80 PRAX

-6.73-1.95%

Praxis Precision Medicines, Inc.$338.57 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

1.2+0.42%

Ligand Pharmaceuticals Incorporated$289.25

Company Overview

Spruce Biosciences, Inc. (NASDAQ:SPRB) closed at $54.35 USD, losing -$1.39 (-2.49%) from the previous close of $55.74. The stock is currently mid-range between its 52-week high and low $7.26 and $240.00. With a market capitalization of about $149.59 million, Spruce Biosciences, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.36). Key stats such as the average daily volume over the past year has been around 77.23 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Spruce Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Javier Szwarcberg, the company employs approximately 22 people and listed since October 09, 2020. Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise.

Technical Performance

SPRB has shown weak momentum, losing -8.15% over the past week and -54.72% over the past quarter, though year-to-date performance is down -17.97%. Short-term trend indicators are mixed aligned (SMA20 -15.09%, SMA50 -22.85%, SMA200 12.84%). The stock’s 14-day RSI is 39.33 (weak momentum), while the ATR of 7.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -75.6% below its high and over 1269.59% above its low. Average 10-day trading volume of 131.64 thousand shares is significantly above the 3-month average of 77.51 thousand, indicating heightened recent market interest.

Valuation Metrics

Spruce Biosciences, Inc. trades at a P/E ratio of -1.33, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.58 suggesting the stock is closer to book value. The P/FCF stands at -3.5, also above market averages.

Dividend & Fair Value

Spruce Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $62.84. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Spruce Biosciences, Inc. generated EPS of -$84.76 over the past year. Five-year average earnings growth is -17.92%. Wall Street analysts project EPS growth of 38.81% annually over the next five years. The latest quarter delivered EPS of -$6.68. The next quarter is forecast at -$9.16. Next year's EPS is expected at -$3.35. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $283.00 to $123.00. The high target offers 420.7% upside. The low target suggests 126.31% downside. The mean target is $186.27. This offers 242.72% upside. Spruce Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by 15.37%. The prior quarter beat by 12.68%. Over the last six quarters, Apple has recorded several small beats. These include 27.98% in May 06, 2025.

Shareholding & Insider Activity

Spruce Biosciences, Inc. has 2.75 million shares outstanding. The public float is 2.65 million shares, elevated short interest at 15.27% of float. This equals 415.86 thousand shares. The short ratio is 4.57 days. Institutional investors hold 79.44% of the float. Insiders own 3.37%. Novo Holdings A/S holds 2.55 million shares, Chaya Moghrabi Dina has 2.16 million shares and Omega Fund VI, L.P. has 2.16 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Spruce Biosciences generated $10.09M in revenue, or $0.26 per share. Gross margin was 99.31%, operating margin -515.34%, and net profit margin -474.96%. Returns are negative, with ROA at -46.10% and ROE at -62.63%.
On valuation metrics, Spruce Biosciences trades at a P/E of -1.33, P/S of 0.00 and P/B of 1.58. The current ratio is 9.23 and quick ratio is 9.23. Debt-to-equity is 0.09, supported by a cash flow-to-debt ratio of -5.56.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Spruce Biosciences posted revenue of $10.09M, down slightly from $0.00 in the prior quarter. Gross profit was $10.02M (margin 99.31%). Operating income was - $51.99M (margin -515.3%). Net income was- $47.92M (EPS - $1.24).
The company ended the quarter with $96.34M in cash and short-term investments, a total debt of $4.61M, and net debt of - $91.73M. Total assets were $103.95M, with equity of $76.51M. Financials further reflected weakness, with operating cash flow of - $33.28M, free cash flow of - $33.28M, and capital expenditures of - $7.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Spruce Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.31%, with price expected at $62.13 by September 24, 2026, within a range of $58.69 to $65.59 3-Month Outlook: Projected rise of 424.75%, reaching $285.20 by December 08, 2026, with a range of $245.13 to $331.88. 1-Year Outlook: Projected loss of -33.76%, with price at $36.00 by September 10, 2027, within a range of $10.95 to $57.44.

Key Takeaways

Spruce Biosciences, Inc. (NASDAQ:SPRB) shares are down -17.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Spruce Biosciences, Inc. trading at a premium to the broader market with a P/E of -1.33. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $81.80, suggesting 50.51% upside. Our AI forecast model points to short-term strength (14.31% over two weeks), a medium-term rise (424.75% over three months), and a longer-term loss (-33.76% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Spruce Biosciences, Inc. (SPRB) stock price?

Spruce Biosciences, Inc. (NASDAQ: SPRB) stock price is $54.35 in the last trading session. During the trading session, SPRB stock reached the peak price of $56.74 while $53.90 was the lowest point it dropped to. The percentage change in SPRB stock occurred in the recent session was -2.49% while the dollar amount for the price change in SPRB stock was - $1.39.

SPRB's industry and sector of operation?

The NASDAQ listed SPRB is part of Biotechnology industry that operates in the broader Healthcare sector. Spruce Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SPRB?

Dr. Libbie Mansell M.B.A., Ph.D.
Chief Regulatory & Quality Officer
Dr. Ralph William Charlton III, M.D.
Chief Medical Officer
Ms. P. J. Ramtin
Senior Vice President of Bus. Operations
Dr. Mojtaba Noursalehi Ph.D.
Senior Vice President of Biometrics
Dr. Javier Szwarcberg M.D., M.P.H.
Chief Executive Officer & Director
Mr. Samir M. Gharib CPA, CPA, M.B.A.
Pres & Chief Financial Officer

How SPRB did perform over past 52-week?

SPRB's closing price is 648.62% higher than its 52-week low of $7.26 where as its distance from 52-week high of $240.00 is -77.35%.

How many employees does SPRB have?

Number of SPRB employees currently stands at 22.

Link for SPRB official website?

Official Website of SPRB is: https://www.sprucebio.com

How do I contact SPRB?

SPRB could be contacted at phone 415 655 4168 and can also be accessed through its website. SPRB operates from 611 Gateway Boulevard, South San Francisco, CA 94080, United States.

How many shares of SPRB are traded daily?

SPRB stock volume for the day was 113.03K shares. The average number of SPRB shares traded daily for last 3 months was 77.23K.

What is the market cap of SPRB currently?

The market value of SPRB currently stands at $149.59M with its latest stock price at $54.35 and 2.75M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	22
Beta	3.34
Sales or Revenue	$10.09M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SPRB Company Profile and Key Details

Spruce Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook